BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021
BioDelivery Sciences International (NASDAQ: BDSI) will report its Q1 2021 financial results on May 6, 2021, prior to the U.S. market opening.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioDelivery Sciences International (NASDAQ: BDSI) will report its Q1 2021 financial results on May 6, 2021, prior to the U.S. market opening. A conference call will be held at 8:30 AM Eastern Time to discuss these results and business updates. BDSI specializes in developing therapies for chronic conditions, utilizing its innovative BEMA technology for effective treatment solutions. The company focuses on serious health issues like chronic pain and opioid-induced constipation.
Details
News Market Reaction – BDSI
The recorded move for BDSI in the trading session of this news was -1.80%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RALEIGH, N.C., April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021 financial results before the open of the U.S. financial markets on Thursday, May 6, 2021. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information:
| Date: | Thursday, May 6, 2021 | |
| Time: | 8:30 AM Eastern Time | |
| Domestic: | 877-407-0789 | |
| International: | 201-689-8562 | |
| Conference ID: | 13718097 | |
| Webcast: | http://public.viavid.com/index.php?id=144116 |
About BioDelivery Sciences International, Inc.
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.
© 2021 BioDelivery Sciences International, Inc. All rights reserved.
Contact:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.